Burden of primary influenza and respiratory syncytial virus pneumonia in hospitalized adults: insights from a two‐year multi‐centre cohort study (2017‐2018)

2021 ◽  
Author(s):  
Matteo Boattini ◽  
Lorena Charrier ◽  
André Almeida ◽  
Eirini Christaki ◽  
Torcato Moreira Marques ◽  
...  
Keyword(s):  
Cohort Study ◽  
Respiratory Syncytial Virus ◽  
Virus Pneumonia ◽  
Syncytial Virus

Full compliance with Respiratory syncytial virus prophylaxis was associated with fewer respiratory‐related hospital admissions in preterm children: A cohort study

2020 ◽  
Author(s):  
Heloise Torchin ◽  
Marie‐Laure Charkaluk ◽  
Jessica Rousseau ◽  
Laetitia Marchand‐Martin ◽  
Ludovic Treluyer ◽  
...  
Keyword(s):  
Cohort Study ◽  
Respiratory Syncytial Virus ◽  
Hospital Admissions ◽  
Preterm Children ◽  
Full Compliance ◽  
Syncytial Virus

scholarly journals Efficacy and safety of interferon on neonates with respiratory syncytial virus pneumonia

2020 ◽  
Vol 20 (6) ◽  
pp. 1-1
Author(s):  
Lingyun He ◽  
Lu Yang ◽  
Hua Zhang ◽  
Qian Luo
Keyword(s):  
Respiratory Syncytial Virus ◽  
Efficacy And Safety ◽  
Virus Pneumonia ◽  
Syncytial Virus

Asthma and Immunoglobulin E Antibodies After Respiratory Syncytial Virus Bronchiolitis: A Prospective Cohort Study With Matched Controls

PEDIATRICS ◽  
1995 ◽  
Vol 95 (4) ◽  
pp. 500-505 ◽  
Author(s):  
N. Sigurs ◽  
R. Bjarnason ◽  
F. Sigurbergsson ◽  
B. Kjellman ◽  
B. Björkstén
Keyword(s):  
Risk Factor ◽  
Cohort Study ◽  
Respiratory Syncytial Virus ◽  
Prospective Cohort ◽  
Egg White ◽  
Control Group ◽  
Igg Antibodies ◽  
Ige Antibodies ◽  
Syncytial Virus

Objective. To study the occurrence of bronchial obstructive symptoms and immunoglobulin (Ig) E antibodies after respiratory syncytial virus (RSV) bronchiolitis in infancy. Previous studies of this subject have mostly been retrospective or without controls, or the controls have not been followed prospectively. Design. This was a prospective cohort study with matched controls. Participants. Forty-seven infants had experienced RSV bronchiolitis severe enough to cause hospitalization at a mean age of 3½ months. For each child with RSV infection, two controls were acquired from the local Child Health Center and matched for date of birth, sex, and residence. Only one control was obtained for one RSV child, and the control group thus contained 93 children. Methods. All the children underwent two follow-up examinations, the first one at a mean age of 1 year and the second at a mean age of 3 years. At the first follow-up, a skin-prick test against egg white was performed, and serum IgG antibodies against RSV were measured. At the second follow-up, serum IgE antibodies were measured using screening tests for common food and inhalant antibodies, and skin-prick tests against egg white, cat, birch, and mite allergen were performed. Hereditary and environmental factors (passive smoking, indoor furred animals) and duration of breast-feeding were recorded. Results. At the first follow-up, 89% in the RSV group and 27% in the control group had IgG antibodies against RSV (P < .001). At the second follow-up, asthma, defined as three episodes of bronchial obstruction verified by a physician, was found in 11 of 47 children (23%) in the RSV group and in 1 of 93 children (1%) in the control group (P < .001). A positive test for IgE antibodies was noted in 14 of 44 (32%) RSV children and in 8 of 92 (9%) children in the control group (P = .002). An analysis of risk factors for the development of asthma and IgE antibodies on the whole group of 140 children showed that RSV bronchiolitis was the most important risk factor, and a family history of atopy or asthma further increased the risk. Conclusions. Respiratory syncytial virus bronchiolitis during the first year of life apparently is an important risk factor for the development of asthma and sensitization to common allergens during the subsequent 2 years, particularly in children with heredity for atopy/asthma.

ASTHMA AND IMMUNOGLOBULIN E (IgE) ANTIBODIES AFTER RESPIRATORY SYNCYTIAL VIRUS (RSV) BRONCHIOLITIS: A PROSPECTIVE COHORT STUDY WITH MATCHED CONTROLS

PEDIATRICS ◽  
1996 ◽  
Vol 98 (2) ◽  
pp. 329-329
Author(s):  
James E. Gern
Keyword(s):  
Risk Factor ◽  
Cohort Study ◽  
Respiratory Syncytial Virus ◽  
Family History ◽  
Prospective Cohort ◽  
Immunoglobulin E ◽  
Specific Ige ◽  
Ige Antibodies ◽  
History Of ◽  
Syncytial Virus

RSV bronchiolitis was the most important risk factor for the development of asthma and allergen-specific IgE, although a family history of atopy or asthma further increased the risk.

scholarly journals Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation.

1996 ◽  
Vol 40 (11) ◽  
pp. 2555-2557 ◽  
Author(s):  
D M Lewinsohn ◽  
R A Bowden ◽  
D Mattson ◽  
S W Crawford
Keyword(s):  
Respiratory Syncytial Virus ◽  
Phase I ◽  
Phase I Study ◽  
Drug Exposure ◽  
The United States ◽  
Marrow Transplant ◽  
Transplant Recipients ◽  
Virus Pneumonia ◽  
Syncytial Virus ◽  
Clinically Significant

Respiratory syncytial virus (RSV) pneumonia in marrow transplant recipients is associated with significant mortality. Ribavirin is a nucleoside analog with activity against RSV and in its aerosolized formulation is the only drug approved for treatment of RSV pneumonia in the United States. The clinical use of aerosolized ribavirin has been limited by caregivers' concerns about drug exposure and potential teratogenic effects. Since there is lack of proven efficacy and safety of the aerosolized ribavirin in this setting, we performed a phase I study of intravenous ribavirin treatment. Between November 1993 and May 1994, 10 patients with clinically significant RSV pneumonia at the Fred Hutchinson Cancer Research Center were enrolled. Only 2 of the 10 survived (20%; 95% CI, 3-56). Two of the 10 patients developed acute hemolysis that necessitated discontinuation of the medication. In conclusion, treatment of marrow transplant recipients with RSV pneumonia with intravenous ribavirin did not improve mortality compared with historical controls treated with the aerosolized drug.

Treatment of Respiratory Syncytial Virus Pneumonia in a Lung Transplant Recipient: Case Report and Review of the Literature

2004 ◽  
Vol 24 (7) ◽  
pp. 932-938 ◽  
Author(s):  
Jeremy D. Flynn ◽  
Wendell S. Akers ◽  
Mikael Jones ◽  
Natasa Stevkovic ◽  
Thomas Waid ◽  
...  
Keyword(s):  
Case Report ◽  
Respiratory Syncytial Virus ◽  
Transplant Recipient ◽  
Lung Transplant ◽  
Lung Transplant Recipient ◽  
Review Of The Literature ◽  
Virus Pneumonia ◽  
Syncytial Virus

Respiratory Syncytial Virus Pneumonia

2006 ◽  
pp. 617-628
Author(s):  
Ann R. Falsey
Keyword(s):  
Respiratory Syncytial Virus ◽  
Virus Pneumonia ◽  
Syncytial Virus

Respiratory syncytial virus pneumonia in hospitalized adults

1991 ◽  
Vol 151 (12) ◽  
pp. 2477-2477
Author(s):  
M. H. Zaroukian
Keyword(s):  
Respiratory Syncytial Virus ◽  
Virus Pneumonia ◽  
Syncytial Virus

Cytologic Manifestations of Respiratory Syncytial Virus Pneumonia in Bronchoalveolar Lavage Fluid

1996 ◽  
Vol 40 (3) ◽  
pp. 546-551 ◽  
Author(s):  
S. Saeed Zaman ◽  
John T. Seykora ◽  
Richard L. Hodinka ◽  
Prabodh K. Gupta ◽  
Giuseppe G. Pietra
Keyword(s):  
Respiratory Syncytial Virus ◽  
Bronchoalveolar Lavage ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Virus Pneumonia ◽  
Syncytial Virus
Sign in / Sign up

Export Citation Format

Share Document